Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study

Diabetes Research and Clinical Practice

Volumn 93, Issue 1, 2011, Pages

  Wägner, Ana María ^a,b,c   Sánchez Quesada, Jose Luis ^d   Benítez, Sonia ^d   Bancells, Cristina ^d,e   Ordóñez Llanos, Jordi ^d,e   Pérez, Antonio ^d,f  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^c UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Atorvastatin; C reactive protein; Gemfibrozil; Inflammation markers; Phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; C REACTIVE PROTEIN; GEMFIBROZIL; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; SECRETORY PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRIC ACIDS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MALE; MIDDLE AGED; PHOSPHOLIPASES A2; PHOSPHOLIPASES A2, SECRETORY; PYRROLES;

EID: 79960556707     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.03.009     Document Type: Article

References (14)

1. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
3. Wägner A.M., Jorba O., Bonet R., Ordóñez-Llanos J., Pérez A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2003, 88:3212-3217.
4. The ACCORD Study Group Effects of combination lipid therapy in type2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
5. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
6. Wang T.-D., Chen W.-J., Lin J.-W., Cheng C.-C., Chen M.-F., Lee Y.-T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003, 170:315-323.
7. Koh K.K., Quon M.J., Han S.H., Cung W.J., Ahn J.Y., Choi I.S., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
8. Sebestjen M., Keber I., Zegura B., Simcic S., Bozic M., Fressart M.M., et al. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Thromb Haemost 2004, 92:1129-1135.
9. Muhlestein J.B., May H.T., Jensen J.R., Horne B.D., Lanman R.B., Lavasani F., et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia. The DIACOR (Diabetes and combined lipid therapy regimen) study. J Am Coll Cardiol 2006, 48:396-401.
10. Derosa G., Maffioli P., Salvadeo S.A.T., Ferrari I., Gravina A., Mereu R., et al. Fenofibrate, simvastatin and their combination in the management of dyslipemia in type 2 diabetic patients. Curr Med Res Opin 2009, 25:1973-1983.
11. O'Donoghue M., Morrow D.A., Sabatine M.S., Murphy S.A., McCabe C.H., Cannon C.P., et al. Lipoprotein-associated phosholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113:1745-1752.
12. Schaefer E.J., McNamara J.R., Asztalos B.F., Tayler T., Daly J.A., Gleason J.L., et al. Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 2005, 95:1025-1032.
13. Menschikowski M., Hagelgans A., Siegert G. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases?. Prostaglandins Other Lipid Mediat 2006, 79:1-33.
14. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Müller M.R., Husslein P., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8 and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002, 22:1194-1199.